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Organ transplant recipients (OTR) are at increased risk of cutaneous squamous cell carcinoma, which
may be related to reactivation of human papillomavirus (HPV) infections. Measurement of change in
HPV antibodies after transplantation would help to explore this hypothesis.
We measured antibodies to 34 HPV types on up to six occasions over 18 months in 441 OTRs from
ﬁve European countries.
At baseline (mean 24 days after transplantation), 80% of all OTRs were seropositive to at least one
HPV type. The beta HPV genus had the highest seroprevalence (45%). For most HPV genera baseline
seroprevalence peaked between 40 and 59 years old. Most OTRs retained their serostatus over time and
antibody levels were stable.
Seroprevalence in immunosuppressed OTRs is stable in the 18 months immediately after trans-
plantation. Thus there is no short-term evidence that immunosuppression leads to new or reactivated
skin infection with HPV sufﬁcient to induce antibodies.
& 2012 Elsevier Inc. All rights reserved.Introduction
Papillomaviruses are small double-stranded DNA viruses that
infect the epithelial cells of skin and mucosa. To date more than
150 human papillomavirus (HPV) types have been fully charac-
terised, and are grouped into ﬁve genera based on phylogenetic
DNA analysis (Bernard et al., 2010). The alpha genus contains
types that infect mucosa and skin, but the majority of skin HPV
types are found in the beta, gamma, mu and nu genera.ll rights reserved.
dical Research, 300 Herston
7 3845 3502.
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are given in Appendix A.Keratinocytic skin cancer (KC) is the most commonly diag-
nosed type of cancer among fair-skinned populations worldwide.
Squamous cell carcinoma (SCC) is the form of KC that can
metastasise, and is more fatal than the more common form, basal
cell carcinoma (BCC). Organ transplant recipients (OTRs) who
receive immunosuppressive therapy have an increased incidence
of cutaneous neoplasia compared to the general population and a
reversal of the usual BCC:SCC ratio (Bouwes Bavinck et al., 2001;
Nindl and Rosl, 2008; Stark et al., 1994). More than 90% of OTRs
develop skin warts and up to 40% develop skin cancer within 15
years of transplantation (Birkeland et al., 1995). These patients
have an up to 100-fold increased risk of SCC and 10-fold increased
risk of BCC of the skin (Kiviat, 1999), a 3-fold increase in cervical
cancer that is solely caused by mucosal HPV (Vajdic et al.,
2006) and an approximate 4-fold increased overall cancer risk,
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causes of the cancers that develop in OTRs include environmental
and genetic factors, but the main factor is believed to be loss of
immune control of oncogenic viruses. The type of drugs used for
immunosuppression, the duration of treatment and the age of the
patient also inﬂuence both the incidence and the type of cancer
that develops (Dantal et al., 1998).
The majority of KCs develop on sun-exposed sites of the body
and solar ultraviolet (UV) radiation is the major cause (Frost and
Green, 1994). Many studies have also suggested a role for HPV in
the carcinogenesis of KC, particularly SCC, and some speciﬁc types
of HPV, including HPV-5, HPV-8, HPV-20 and HPV-77, have been
shown to be activated by UV radiation (Akgul et al., 2005; Purdie
et al., 1999; Ruhland and de Villiers, 2001). UV-induced onco-
genicity of the HPV proteins E6/E7 and transcriptional activity of
HPVE6/E7 in KC have also been described (Dang et al., 2006;
Michel et al., 2006). Furthermore, differences in in vitro trans-
forming activity potential between various cutaneous HPV types
have been shown, providing further evidence for a role of speciﬁc
cutaneous HPV in the development of KC (Massimi et al., 2008).
Despite these ﬁndings no cutaneous high-risk HPV type with a
role in KC has yet been identiﬁed.
The natural history of HPV in cervical cancer has been studied
extensively, and antibodies have been identiﬁed as markers of
past and present infections (Dillner, 1999). It is known that only
50% of women infected with the mucosal high-risk HPV type 16
develop antibodies to HPV-16, and this can take several months
up to a year after initial infection. Once presence of HPV-16
antibodies is established, low but stable titres are detectable over
at least 10 years (Dillner, 1999). In comparison, little is known
about the natural history of antibodies to HPV types infecting
skin. As with mucosal types, it appears that only approximately
half of the people with a speciﬁc HPV type on the skin generate
type-speciﬁc antibodies. The presence of antibodies reﬂects past
or present exposure, individual immunological status and genetic
susceptibility and possibly also the viral load. The presence of
antibodies has been shown to be associated with cutaneous SCC
(Bouwes Bavinck et al., 2010; Feltkamp et al., 2003; Karagas et al.,
2006; Proby et al., 2011).
HPV antibody levels (measured as MFI) and serostatus in
people who are not iatrogenically immunosuppressed are stable
over time (Antonsson et al., 2010) but knowledge about what
happens to antibodies to mucosal and cutaneous HPV types
within the context of immunosuppression is limited. Understand-
ing the natural history of antibodies after immunosuppression
is initiated may help to further elucidate the reason for the
markedly elevated risk of cutaneous SCC in people who have
undergone organ transplantation.
We therefore determined the stability of antibody status of
34 HPV types among 441 OTRs from ﬁve European countries in
the immediate short-term, namely, over the ﬁrst 18-months
post transplantation. We further analysed factors that may be
associated with the presence of antibodies and with change in
antibody status over time. To our knowledge, this paper describes
for the ﬁrst time a longitudinal study of HPV antibodies in OTRs.Results
Participants and samples
Serum samples from 441 organ transplant recipients (OTRs)
were analysed: 100 participants from Bergamo (Italy), 90 from
Berlin (Germany), 101 from Leiden (the Netherlands), 100 from
Lyon (France), and 50 from London (UK).The mean age at baseline was 48 years and 65% of participants
were men (Table 1). Other basic characteristics of the participants
studied are presented in Table 1. The mean follow-up time was
463 days (SD 138 days) and the mean time between blood
collection time points was 85 days (SD 45 days) until time point
4 (12 months) and 176 days (SD 48 days) between time points
4 and 5 (18 months). Seventy-three percent of patients (N¼320)
were followed up for a year or longer, and there was no difference
in the age or sex distributions of these patients compared with all
those recruited. However there was a difference in the proportion
of OTRs followed up for a year or more by country with the
highest proportion of follow up in the Leiden group (86%; n¼87)
and the lowest in London (48%; n¼24). Forty-eight percent of the
participants had six samples collected, 24% ﬁve samples, 10% four,
5% two and three samples, and 8% had one sample collected
(these 8% were used in the baseline analyses only).
HPV seroprevalence
At the time of the ﬁrst blood collection, 80% of the OTRs were
seropositive to at least one of the HPV types for which we tested.
The seroprevalence at baseline was highest for the beta HPV types
(45%), followed by the gamma genus (44%), the mucosal alpha
HPV types (33%), the mu and nu genera (32%), and was lowest for
the cutaneous alpha types (23%). Type-speciﬁcally, HPV-6 and
HPV-4 had the highest seroprevalences at baseline (28% and 26%,
respectively) followed by HPV-1 (21%; Fig. 1). HPV-93 (4%), HPV-7
(5%) and HPV-13 (5%) (Fig. 1) had the lowest seroprevalence.
Fifty-seven of the 86 people (66%) that were seronegative at
baseline kept their seronegative status over time. In the group of
29 OTRs (7%) that were seronegative at baseline but then gained
seropositivity over time, we found that it was most common to
seroconvert to a beta HPV type followed by, gamma, mucosal
alpha, cutaneous skin and mu/nu HPV types. Eighty-seven percent
of the OTRs were seropositive in at least one sample over time.
Associations at baseline between seropositivity and participant
characteristics
For 25 out of 34 HPV types we found a signiﬁcant association
between increasing age and baseline seroprevalence, with sero-
prevalence peaking between 41 and 60 years and decreasing
thereafter (supplementary Table 1). When we grouped the types
into genera, this pattern was apparent for all genera except mu
and nu and the cutaneous alpha HPV types, but was only
signiﬁcant for the beta HPV genus (p¼0.0005; Table 2).
Our analysis of MFI as a continuous variable supported the
above ﬁndings. Linear regression (adjusted for sex) was used to
identify trends in MFI values across the different age categories.
The MFI was highest in the age group 50–59 years for all HPV
types, with the exception of the two mucosal alpha HPV types
HPV-6 and HPV-16 (data not shown). HPV-6 had the peak of MFI
in the age group 40–49 (po0.0001) and HPV-16 MFI increased
with age (p¼0.0003). We found no consistent associations
between sex and seropositivity (data not shown) or MFI for any
HPV types.
Generally, current smokers had a higher seroprevalence for
most HPV types compared to former smokers and non-smokers,
although this was only signiﬁcant for HPV-41 (non-smokers 7%,
smokers 19% and ex-smokers 13%; p¼0.020) (HPV type-speciﬁc
data not shown). When we grouped the viruses into genera,
smoking was not signiﬁcantly associated with higher seroposi-
tivity for any particular HPV genus after adjustment for age, sex
and centre (Table 2).
Overall, OTRs with no current warts had higher seroprevalence
to most of the HPV types analysed (type-speciﬁc data not shown).
Table 1
Characteristics of study population at baseline (n¼441).
Characteristic % (n) P-value
All Bergamo Berlin Leiden London Lyon
n 441 100 90 101 50 100
Sex
Female 35.4 (156) 29.0 (29) 38.9 (35) 33.7 (34) 36.0 (18) 40.0 (40) 0.494
Male 64.6 (285) 71.0 (71) 61.0 (55) 66.3 (67) 64.0 (32) 60.0 (60)
Age
Age distribution
Mean (SD) 47.6 (13.2) 47.9 (13.3) 48.3 (14.7) 47.0 (12.4) 45.9 (127) 48.2 (13.1)
up to 30 10.9 (47) 13.0 (13) 12.2 (11) 8.9 (9) 12.0 (6) 8.0 (8) 0.355
31–40 20.6 (91) 12.0 (12) 22.2 (20) 23.8 (24) 18.0 (9) 26.0 (26)
41–50 23.5 (104) 26.0 (26) 22.2 (20) 23.8 (24) 32.0 (16) 18.0 (18)
51–60 24.0 (16) 27.0 (27) 17.8 (16) 28.7 (29) 20.0 (10) 24.0 (24)
61 and older 21.0 (93) 22.0 (22) 25.6 (23) 14.8 (15) 18.0 (9) 24.0 (24)
Organ(s) transplanted
Kidney 87.6 (386) 100.0 (100) 98.9 (89) 82.2 (83) 100.0 (50) 64.0 (64) o0.0001
Heart 4.3 (9) 0 0 0 0 19.0 (19)
Kidney and heart 0.2 (1) 0 0 0 0 1.0 (1)
Kidney and pancreas 7.9 (35) 0 1.1 (1) 17.8 (18) 0 16.0 (16)
Skin phototype
Dark/olive 48.6 (215) 70.0 (70) 6.7 (6) 56.4 (57) 34.0 (17) 65.0 (65) o0.0001
Medium 35.8 (158) 29.0 (29) 54.4 (49) 38.6 (39) 42.0 (21) 20.0 (20)
Fair 15.6 (68) 1.0 (1) 38.9 (35) 5.0 (5) 24.0 (12) 15.0 (15)
Eye colour
Brown 45.2 (200) 59.0 (59) 32.2 (29) 36.6 (37) 38.0 (19) 56.0 (56) 0.0001
Green/blue/grey 54.8 (241) 41.0 (41) 67.8 (61) 63.4 (64) 62.0 (31) 44.0 (44)
Hair colour
Black/brown 61.8 (273) 78.0 (78) 45.6 (41) 34.6 (35) 80.0 (40) 79.0 (79) o0.0001
Dark blonde/blonde/red 38.2 (168) 22.0 (22) 54.4 (49) 65.4 (66) 20.0 (10) 21.0 (21)
Tanning
Tan only 48.8 (214) 67.0 (67) 6.8 (6) 58.4 (59) 34.0 (17) 65.0 (65) o0.0001
Burn then tan 38.0 (167) 29.0 (29) 55.7 (49) 34.7 (35) 42.0 (21) 33.0 (33)
Burn only 13.2 (58) 4.0 (4) 37.5 (33) 6.9 (7) 24.0 (12) 2.0 (2)
Reaction to ﬁrst bright sun at midday
Never sunbath 19.0 (84) 36.0 (36) 0 9.9 (10) 50.0 (25) 13.0 (13) o0.0001
Hardly any reaction 27.7 (122) 37.0 (37) 6.7 (6) 61.4 (62) 18.0 (9) 8.0 (8)
A little bit of red colouring 24.9 (110) 22.0 (22) 59.4 (49) 14.8 (15) 22.0 (11) 13.0 (13)
Sunburned 20.0 (88) 5.0 (5) 36.7 (33) 36.6 (33) 10.0 (5) 33.0 (33)
Painfully burned 7.9 (35) 0 2.2 (2) 2.2 (2) 0 31.0 (31)
Blistering 0.5 (2) 0 0 0 0 2.0 (2)
Painful sunburns before 20 yrs
Never 50.6 (221) 69.0 (69) 67.8 (61) 40.6 (41) 56.2 (27) 23.5 (23) o0.0001
1–4 sunburns 34.5 (151) 26.0 (26) 26.7 (24) 41.6 (42) 29.2 (14) 45.9 (45)
5 and more sunburns 14.9 (65) 5.0 (5) 5.6 (5) 17.8 (18) 14.6 (7) 30.6 (30)
Smokinga
Never smoked 42.2 (186) 45.0 (45) 50.0 (45) 37.6 (38) 32.6 (16) 42.0 (42) 0.004
Current smoker 10.2 (44) 1.0 (1) 12.2 (11) 10.9 (11) 24.5 (12) 9.0 (9)
Ex-smoker 47.6 (210) 54.0 (54) 37.8 (34) 51.5 (52) 42.9 (21) 49.0 (49)
Alcohol consumptiona
None 56.6 (225) 66.0 (66) 69.3 (61) 61.4 (62) 31.1 (14) 34.0 (22) o0.0001
Low 35.1 (140) 29.0 (29) 26.1 (23) 35.6 (36) 55.6 (25) 42.0 (27)
Medium/high 8.3 (33) 5.0 (5) 4.6 (4) 3.0 (3) 13.3 (6) 24.0 (15)
European born
Yes 96.6 (426) 98.0 (98) 98.9 (89) 97.0 (98) 100.0 (50) 91.0 (91) 0.009
No 3.4 (15) 2.0 (2) 1.1 (1) 3.0 (3) 0 9.0 (9)
Educationa
School only 57.5 (253) 66.0 (66) 75.3 (67) 42.6 (43) 30.6 (16) 61.0 (61) o0.0001
Tech/diploma 17.5 (77) 11.0 (11) 0 17.8 (18) 49.0 (24) 24.0 (24)
College/university 25.0 (110) 23.0 (23) 24.7 (89) 39.6 (40) 20.4 (10) 15.0 (15)
a Numbers do not sum to total due to missing data.
A. Antonsson et al. / Virology 436 (2013) 91–99 93This association was signiﬁcant for HPV-48 (no warts 14% and
warts 2%; p¼0.017), HPV-101 (no warts 9% and warts 0%;
p¼0.030) and HPV-3 (no warts 9% and warts 0%; p¼0.030).We found no other overall associations with seropositivity
(Table 2) or MFI (data not shown) and other participant char-
acteristics examined.
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Fig. 1. Seroprevalence at baseline for the 34 HPV antibodies analysed.
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Our longitudinal observations are based on 406 participants
who had more than one sample collected. After adjustment for
age, sex and centre, there was no consistent increase or decrease
in seroprevalence over time for any speciﬁc HPV genus (Table 2)
or type. Similarly, we found no signiﬁcant trend in MFI values
over time (supplementary Table 2).
We did not ﬁnd a consistent increase or decrease in the
number of antibody types detected. Among patients who were
seropositive at baseline the median number of antibody types
found was 3 at both baseline and at ﬁnal follow-up. Forty percent
of participants gained seropositivity to one or more HPV types,
29% had the same number of antibody types detected at baseline
and at ﬁnal follow-up and 31% had fewer antibody types detected
at the end of the study.
Most participants were stably seronegative or seropositive
over time for all HPV types (Table 3). The HPV types with the
highest proportion of participants who had stable serostatus were
HPV-93 (95% stable serostatus), and HPV-3, HPV-7 and HPV-60
(all three 94%). The HPV types with the highest change in
serostability over time were HPV-6 (21% changed serostatus),
HPV-4 (15%), and HPV-8 and HPV-65 (both 14%). Ninety percent
or more of OTRs seronegative at baseline stayed seronegative over
time for the majority of HPV types. OTRs seropositive at baseline
were less serostable over time than those who were seronegative
at baseline. For most HPV types 60% or more kept their seropo-
sitive status over time (Table 3). There was no difference
in serostability for any of the HPV types in patients that were
sampled over a time period of less than a year compared to
patients who were followed for a year or longer.
When stratiﬁed by HPV status at baseline, we found no
associations between age, sex, eye colour, hair colour, alcohol
consumption, smoking, country of birth or education and
serostability for any of the HPV types examined (data not
shown).Discussion
Very little is known about the natural history of HPV types or
their antibodies in immunosuppressed people, particularly over
time. We analysed seroprevalence and antibody stability to 34
HPV types in 441 OTRs. Eighty percent of all OTRs had at least one
sample seropositive to at least one of the HPV types analysed at
baseline. Previous seroprevalence studies in OTRs that are up to
15 years post transplantation have shown similar results with a
range from 86% to 94% (Casabonne et al., 2009a,b,c; Proby et al.,
2011). Reports in immunocompetent people have been more
varied, where some studies have shown high seroprevalence
(86–91%) (Antonsson et al., 2010; Casabonne et al., 2009a;
Iannacone et al., 2010), and others have been considerably lower
(20–60%) (Bouwes Bavinck et al., 2010; Casabonne et al., 2007;
Michael et al., 2008).
We found the highest seroprevalence for the mucosal alpha
type HPV-6 (28% at baseline; 26% at 18 months post transplanta-
tion). In the majority of previous studies describing HPV seropre-
valence in OTRs, HPV-6 has been the most common HPV type
(29–33%) (Casabonne et al., 2009a,b,c; Lally et al., 2010;
Sampogna et al., 2012). Antibodies to HPV-6 are also very
common in the general healthy European population, with
reported seroprevalences in two different studies of 20 and 40%
(Newall et al., 2008; Waterboer et al., 2009). The gamma type,
HPV-4, had similarly high seroprevalence (26% at baseline). High
seroprevalence to HPV-4 has commonly been reported in pre-
vious studies of both OTRs (Casabonne et al., 2009a,b,c) and
immunocompetent people (Casabonne et al., 2007, 2009c;
Iannacone et al., 2010; Waterboer et al., 2009). HPV-4 infection
is highly prevalent in the general population, particularly in
children and teenagers, as it causes common warts (Chen et al.,
1993; Kilkenny et al., 1998; Pﬁster and zur Hausen, 1978).
Overall, the HPV type-speciﬁc seroprevalences reported here
in OTRs at baseline and after 18 months are similar to those
previously reported for Caucasian OTRs and the general
Table 2
Associations between seropositivity, basic characteristics and time points for the different HPV genera (logistic regression adjusted for age, sex and country).
Characteristic b HPVa P-value/
trendn
g HPVb P-value/
trendn
m/n HPVc P-value/
trendn
Skin a-HPVd P-value/
trendn
Mucosal a-HPVe P-value/
trendn
% OR (95% CI) % OR (95% CI) % OR (95% CI) % OR (95% CI) % OR (95% CI)
Age distribution
up to 29 27.9 1.00 0.0005n 46.3 1.00 0.450n 38.8 1.00 0.579n 20.9 1.00 0.498n 37.8 1.00 0.120n
30–39 38.8 1.13 (1.03–1.23) 44.7 0.91 (0.75–1.12) 31.9 0.98 (0.91–1.06) 19.7 1.02 (0.95–1.10) 32.4 0.97 (0.87–1.07)
40–49 52.0 1.22 (1.10–1.34) 50.7 0.98 (0.81–1.18) 39.9 1.04 (0.94–1.15) 20.0 1.01 (0.92–1.11) 37.8 0.98 (0.87–1.11)
50–59 61.3 1.30 (1.17–1.44) 54.9 1.00 (0.84–1.20) 37.5 0.95 (0.85–1.06) 29.6 1.06 (0.96–1.17) 36.0 0.97 (0.86–1.09)
60 and older 49.0 1.25 (1.11–1.40) 47.4 0.99 (0.83–1.19) 30.4 0.98 (0.86–1.10) 24.4 1.03 (0.93–1.14) 26.0 0.90 (0.80–1.01)
Sex
Female 49.5 1.00 0.910 54.8 1.00 0.111 40.2 1.00 0.080 27.5 1.00 0.438 38.0 1.00 0.161
Male 49.0 1.00 (0.91–1.09) 46.6 0.93 (0.85–1.02) 33.1 0.92 (0.85–1.01) 21.3 0.97 (0.90–1.05) 31.4 0.94 (0.87–1.02)
Skin phototype
Dark/olive 50.6 1.00 0.108 44.6 1.00 0.213 31.1 1.00 0.231 20.7 1.00 0.662 31.8 1.00 0.535
Medium 44.1 0.91 (0.83–1.00) 51.6 1.05 (0.96–1.15) 38.8 1.05 (0.95–1.15) 27.3 1.04 (0.96–1.12) 37.7 1.03 (0.95–1.13)
Fair 56.9 1.01 (0.90–1.15) 60.9 1.11 (0.98–1.26) 43.1 1.11 (0.98–1.25) 23.4 1.02 (0.91–1.13) 30.4 0.97 (0.87–1.08)
Eye colour
Brown 50.0 1.00 0.263 46.4 1.00 0.465 34.3 1.00 0.593 23.2 1.00 0.830 35.1 1.00 0.583
Green/blue/grey 48.5 0.95 (0.88–1.04) 52.0 1.03 (0.95–1.12) 36.6 1.02 (0.94–1.11) 23.6 1.01 (0.94–1.09) 32.5 0.98 (0.90–1.06)
Hair colour
Black/brown 48.6 1.00 0.766 46.5 1.00 0.130 35.1 1.00 0.808 22.8 1.00 0.720 35.1 1.00 0.351
Dark blonde/blonde/
red
50.1 1.01 (0.93–1.10) 53.8 1.07 (0.98–1.17) 36.2 1.01 (0.93–1.10) 24.5 1.01 (0.94–1.09) 31.6 0.96 (0.89–1.04)
Smoking
Never 46.4 1.00 0.744 52.0 1.00 0.434 30.6 1.00 0.092 21.4 1.00 0.435 33.2 1.00 0.147
Current 49.2 1.02 (0.88–1.18) 57.1 1.06 (0.91–1.24) 40.3 1.14 (0.98–1.33) 27.2 1.08 (0.95–1.23) 42.4 1.17 (1.01–1.35)
Ex-smoker 51.6 1.02 (0.94–1.12) 46.0 0.96 (0.88–1.06) 39.1 1.10 (1.01–1.21) 24.6 1.04 (0.96–1.13) 32.5 1.00 (0.92–1.10)
Alcohol consumptionf
None 45.0 1.00 0.076 50.0 1.00 0.961 33.4 1.00 0.417 22.6 1.00 0.512 31.5 1.00 0.732
Low 58.5 1.11 (1.01–1.22) 50.2 0.99 (0.90–1.09) 39.9 1.06 (0.96–1.17) 24.8 1.04 (0.96–1.13) 33.7 1.03 (0.94–1.12)
Medium/high 47.6 1.00 (0.85–1.19) 43.3 0.98 (0.83–1.15) 35.4 1.08 (0.91–1.27) 15.8 0.97 (0.84–1.11) 34.1 1.05 (0.90–1.23)
European born
Yes 48.3 1.00 0.098 49.4 1.00 0.871 43.7 1.00 0.563 23.4 1.00 0.103 43.7 1.00 0.379
No 71.2 0.99 (0.91–1.08) 48.7 0.93 (0.85–1.01) 35.2 0.92 (0.85–1.00) 12.5 0.97 (0.90–1.05) 33.3 0.94 (0.87–1.02)
Educationf
School only 48.9 1.00 0.923 49.2 1.00 0.961 35.4 1.00 0.943 25.0 1.00 0.711 32.7 1.00 0.866
Tech/diploma 50.4 1.02 (0.91–1.14) 47.9 1.00 (0.88–1.12) 35.3 1.00 (0.89–1.12) 21.3 0.98 (0.84–1.09) 32.5 1.02 (0.92–1.14)
College/university 49.1 0.99 (0.90–1.10) 51.3 0.99 (0.89–1.09) 36.3 1.02 (0.92–1.13) 21.6 0.96 (0.89–1.05) 36.8 1.02 (0.93–1.12)
Time pointsg
0 45.2 1.00 0.161n 44.3 1.00 0.057n 33.2 1.00 0.170n 23.0 1.00 0.941n 33.5 1.00 0.699n
1 50.1 1.05 (1.02–1.09) 49.9 1.05 (1.01–1.08) 35.2 1.03 (1.00–1.07) 24.1 1.01 (0.98–1.04) 34.6 1.02 (0.98–1.05)
2 48.9 1.04 (1.00–1.07) 51.3 1.07 (1.03–1.11) 37.5 1.06 (1.02–1.09) 22.9 1.00 (0.97–1.03) 31.8 1.01 (0.98–1.06)
3 50.5 1.05 (1.01–1.09) 49.2 1.04 (1.00–1.08) 35.4 1.04 (1.00–1.07) 23.1 1.01 (0.98–1.05) 33.8 1.02 (0.98–1.06)
4 49.1 1.05 (1.01–1.09) 49.7 1.06 (1.02–1.10) 36.2 1.04 (1.01–1.07) 23.9 1.00 (0.97–1.03) 34.0 1.03 (0.99–1.07)
5 53.0 1.06 (1.02–1.10) 54.0 1.07 (1.02–1.11) 37.5 1.04 (1.00–1.07) 24.0 1.03 (1.00–1.06) 34.5 1.04 (1.00–1.09)
a b HPV types analysed; HPV-5, -8, -9, -15, -17, -20, -23, -24, -36, -38, -49, -75, -76, -92, -93, and -96.
b g HPV types; HPV-4, -48,, -50, -60, -65, -95, -101, and -103.
c m/n HPV types; HPV-1, -41, and -63.
d Skin a HPV types; HPV-2, -3, -7, and -27.
e Mucosal a HPV types; HPV-6, -13, and -16.
f n does not sum up to total due to missing data.
g Average time between time points was 91 days.
n P trend.
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Table 3
Serostability status for the different HPV types over time (n¼406).
HPV type % (n)
Seropositive at baseline Seronegative at baseline
n Seropositive Seroreversion Fluctuaters n Seronegative Seroconversion Fluctuaters
HPV-5 47 63.8 (30) 17.0 (8) 19.2 (9) 359 95.0 (341) 1.7 (6) 3.3 (12)
HPV-8 82 68.3 (56) 18.3 (15) 13.4 (11) 324 91.0 (295) 5.6 (18) 3.4 (11)
HPV-9 52 65.4 (34) 23.1 (12) 11.5 (6) 354 96.6 (342) 2.8 (10) 0.6 (2)
HPV-15 72 70.8 (51) 16.7 (12) 12.5 (9) 334 91.3 (305) 4.2 (14) 4.5 (15)
HPV-17 73 74.0 (54) 9.6 (7) 16.4 (12) 333 91.6 (305) 3.9 (13) 4.5 (15)
HPV-20 50 62.0 (31) 22.0 (11) 16.0 (8) 356 95.2 (339) 2.5 (9) 2.2 (8)
HPV-23 46 76.1 (35) 15.2 (7) 8.7 (4) 360 95.6 (344) 1.7 (6) 2.8 (10)
HPV-24 51 74.5 (38) 9.8 (5) 16.7 (8) 355 95.8 (340) 2.0 (7) 2.2 (8)
HPV-36 31 67.8 (21) 29.0 (9) 3.2 (1) 375 94.7 (355) 2.7 (10) 2.7 (10)
HPV-38 75 74.7 (56) 16.0 (12) 9.3 (7) 331 92.8 (307) 3.3 (11) 3.9 (13)
HPV-49 68 75.0 (51) 16.2 (11) 8.8 (6) 338 96.1 (325) 1.8 (6) 2.1 (7)
HPV-75 43 76.8 (33) 11.6 (5) 11.6 (5) 363 93.1 (338) 4.1 (15) 2.8 (10)
HPV-76 38 71.1 (27) 18.4 (7) 10.5 (4) 368 94.6 (348) 2.2 (8) 3.2 (12)
HPV-92 43 67.5 (29) 20.9 (9) 11.6 (5) 363 93.7 (340) 3.9 (14) 2.4 (9)
HPV-93 15 80.0 (12) 13.3 (2) 6.7 (1) 391 95.1 (372) 2.8 (11) 2.1 (8)
HPV-96 51 72.5 (37) 11.8 (6) 15.7 (8) 355 93.2 (331) 4.0 (14) 2.8 (10)
HPV-4 107 78.5 (84) 7.5 (8) 14.0 (15) 299 87.3 (261) 3.7 (11) 9.0 (27)
HPV-48 49 67.4 (33) 24.4 (11) 10.2 (5) 357 93.8 (335) 4.8 (17) 1.4 (5)
HPV-50 23 69.6 (16) 8.7 (2) 21.7 (5) 383 94.8 (363) 3.1 (12) 2.1 (8)
HPV-60 21 57.1 (12) 23.8 (5) 19.1 (4) 385 96.1 (370) 1.8 (7) 2.1 (8)
HPV-65 74 73.0 (54) 16.2 (12) 10.8 (8) 332 89.5 (297) 4.8 (16) 5.7 (19)
HPV-95 64 78.1 (50) 9.4 (6) 12.5 (8) 342 92.1 (315) 3.8 (13) 4.1 (14)
HPV-101 30 86.7 (26) 10.0 (3) 3.3 (1) 376 92.8 (349) 3.7 (14) 3.5 (13)
HPV-103 29 75.9 (22) 13.8 (4) 10.3 (3) 377 95.2 (359) 2.9 (11) 1.9 (7)
HPV-1 84 84.5 (71) 8.3 (7) 7.2 (6) 322 90.4 (291) 4.3 (14) 5.3 (17)
HPV-63 70 82.9 (58) 12.8 (9) 4.3 (3) 336 91.7 (308) 5.4 (18) 2.9 (10)
HPV-41 44 75.0 (33) 15.9 (7) 9.1 (4) 362 94.5 (342) 3.9 (14) 1.6 (6)
HPV-2 38 81.6 (31) 13.1 (5) 5.3 (2) 368 94.3 (347) 3.0 (11) 2.7 (10)
HPV-3 31 58.1 (18) 19.3 (6) 22.6 (7) 375 97.3 (365) 1.6 (6) 1.1 (4)
HPV-7 21 57.1 (12) 23.8 (5) 19.1 (4) 385 96.4 (371) 2.1 (8) 1.6 (6)
HPV-27 44 68.2 (30) 23.7 (10) 9.1 (4) 362 92.0 (333) 3.6 (13) 4.4 (16)
HPV-6 110 65.5 (72) 22.7 (25) 11.8 (13) 296 84.5 (250) 8.1 (24) 7.4 (22)
HPV-13 24 58.4 (14) 20.8 (5) 20.8 (5) 382 95.5 (365) 2.1 (8) 2.4 (9)
HPV-16 31 64.5 (20) 16.1 (5) 19.4 (6) 375 91.2 (342) 4.0 (15) 4.8 (18)
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suggests that this distribution is similar worldwide and is not
strongly dependent on immune status.
In terms of HPV genera, seroprevalence was highest for the
beta genus and lowest for the cutaneous alpha types. However
there was considerable variability in the number of types
included in each genus, so the precision of seroprevalence
estimates may not be directly comparable.
At baseline we found signiﬁcant increasing seroprevalence
with increasing age up to 59 years for most HPV types, with
highest seroprevalence in the age groups between 40 and 59
years, followed by a drop in seroprevalence after 60 years. Similar
results in seroprevalence, with a peak after the age of 40 have
previously been reported for the beta HPV genus in an Italian
general population (Michael et al., 2008; Waterboer et al., 2009).
Cutaneous HPV DNA prevalence in healthy skin has been reported
to increase steadily with age throughout life in immunocompe-
tent people and OTRs with no decrease after the age of 60
(Antonsson et al., 2000; de Koning et al., 2009; Gottschling
et al., 2009; Hazard et al., 2007). Since HPV infection of the skin
appears to increase with age, the decrease in HPV seroprevalence
after the age of 60 could possibly be due to immunosenescence
and decaying antibodies in the aging population.
At baseline current smokers had an overall higher seropreva-
lence compared to non-smokers or former smokers but this was
only signiﬁcant for HPV-41. Previous studies have found signiﬁ-
cant associations with smoking and cutaneous HPV seropositivityin immunocompetent people(Andersson et al., 2008; Antonsson
et al., 2010; Iannacone et al., 2010), but no association has been
found in immunosuppressed OTRs (Casabonne et al., 2009a,b;
Sampogna et al., 2012). It has previously been suggested that
smoking could prolong the duration of mucosal alpha HPV infection
(Giuliano et al., 2002) and smoking is an established cofactor in
cervical carcinogenesis (Castellsague and Munoz, 2003; McIntyre-
Seltman et al., 2005), but the role of smoking in cutaneous HPV
infection and seroconversion is currently unknown.
Warts in the OTR population are not only caused by the HPV
types that cause warts in the general population, but also by HPV
types that would cause subclinical infections in immunocompe-
tent people (Kohler et al., 2011). When we compared OTRs with
and without current skin warts at baseline we found that
participants with no warts had higher overall seroprevalence
than participants with warts. It is possible that this is due to
the generation of antibodies during the process of clearing HPV
infections that cause warts, and that these antibodies protect
against future viral challenges. Cell-mediated immunity that is
suppressed in all solid organ and bone marrow transplant
patients is believed to be the ﬁrst response to HPV infection, with
neutralising antibodies to the major capsid (L1) protein of HPV
being produced later (Stanley, 2009). Once L1 HPV antibodies are
generated they supplement the cell-mediated immune response
to protect against viral challenges by that particular HPV type. In
this immunosuppressed population, during the 18 month time
frame studied here, we did not observe a change in antibody
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tion of antibodies to new antigens requires antigen presentation
by the cell-mediated arm of the immune system. We cannot tell if
antibody stability observed here is because there are no new viral
infections or change in viral load, or if it is because cell-mediated
antigen presentation to new or changed viral infections is ham-
pered by immune suppressive treatment. Also, because we used
an IgG-based sero-assay, we were unable to detect IgM responses
that may have been induced in the absence of a T helper cell
response.
Information about stability of cutaneous HPV antibodies over
time is very limited, with only one study from a healthy popula-
tion to date (Antonsson et al., 2010). We found that the cutaneous
HPV antibodies studied here in OTRs were relatively stable over
time, although we were unable to analyse changes from before to
after transplantation. For most HPV types, 90% or more stayed
either stably seropositive or seronegative over time. Generally,
the cutaneous HPV types with the largest changes in serostatus
were the HPV types with lower seroprevalence, and changes may
be due to statistical instability rather than being a true biological
effect (Antonsson et al., 2010). This is supported by the ﬁnding
that we did not ﬁnd any signiﬁcant increasing or decreasing
trends over time for MFI or seroprevalence.
We found no previous study analysing mucosal type HPV
antibody stability in OTRs. Previous studies of serostability for
the mucosal alpha HPV types in immunocompetent people have
shown that antibody levels are usually very stable over long
periods of time for the high-risk HPV types that cause cervical
cancer (af Geijersstam et al., 1998; Carter et al., 1996; Dillner,
1999; Syrjanen et al., 2009), while antibody levels to the low-risk
HPV types found in genital warts (e.g. HPV-6) seem to be less
stable and to decay over time (Antonsson et al., 2010; Carter et al.,
2000). In this study we found that all mucosal alpha HPV
antibodies were very stable over time and that HPV-6 antibodies
did not decay more over time than other HPV antibodies. How-
ever, people who were HPV-6 negative at baseline were more
likely to seroconvert than people who were seronegative to other
mucosal alpha HPV types.
A limitation of this study is the variation in time after trans-
plantation until the ﬁrst baseline sample was collected. While most
baseline samples were collected within about two weeks of
transplantation there was quite a broad range with one sample
collected 101 days after transplantation. Although the lack of data
regarding HPV serostatus prior to transplantation is a limitation as
it prevents us from analysing changes from before to after immu-
nosuppression, the half-life of IgG antibodies is approximately 26
days, so it is likely that our baseline antibody levels reﬂect those
just prior to transplantation (Mankarious et al., 1988). Furthermore,
the very stable antibody status we observed over a period when
immunosuppressive regimens were likely to be changing suggests
that antibody status close to the time of initiation of immunosup-
pression might be indicative of earlier status.
This study recruited participants in different countries in order to
recruit sufﬁcient numbers of transplant recipients. There were some
demographic differences in participants from different countries, but
the small numbers from each country precluded a statistically
robust analysis of differences in associations or serostability across
countries. However we adjusted for age, sex and country in our
analyses to compensate for the demographic differences.
In conclusion, the seroprevalence and serostability to the HPV
types investigated here is similar to that described for immuno-
competent populations. Understanding the natural history of HPV
in the context of immunosuppression is important, particularly in
terms of elucidating the role of HPV in cutaneous carcinogenesis,
so further research over a longer time frame or using different
measures of immune function and/or HPV is warranted.Materials and methods
Study population and data collection
Patients with recent solid organ transplants were recruited in
the following hospitals: Leiden University Medical Center, Leiden,
The Netherlands; Bart’s and the London NHS Trust, London, UK;
University Clinic Charite´, Berlin, Germany; Hoˆpital Edouard Herriot,
Lyon, France; Ospedali Riuniti di Bergamo, Bergamo, Italy; and
Ospedale Civile Maggiore, Verona, Italy. The aim was to recruit 100
patients that had solid organ transplants from each centre. The
recruitment of patients started in November 2002 and the last
patient was recruited in January 2006. Patients were seen shortly
after transplantation (mean 24 days, range 1 to 101 days after
transplantation), and then on average every 3 months up to 12
months and ﬁnally at approximately 18 months. At each visit, (i)
the patients had skin exams and were checked for keratotic skin
lesions and skin cancer, (ii) blood and plucked eyebrow hairs were
collected, and (iii) a questionnaire was ﬁlled out.
Questionnaires, together with medical charts, were used to
collect information about: sex and age of the patients; type and
number and date/s of solid organ transplantations; level of educa-
tion; UV-related questions, such as ability to tan, sun reactivity, skin
type, occupational sun exposure (during the week), recreational sun
exposure during the weekends, and number of painful sunburns
before the age of 20 years; and other potential risk factors for skin
cancer such as smoking and alcohol consumption. Skin type (skin
phototype) was re-categorized into ‘‘olive’’, ‘‘medium’’, and ‘‘fair’’
depending on responses to the questions about tanning ability, sun
reactivity, and Fitzpatrick skin type (details described in (Bouwes
Bavinck et al., 2007)). Patients with (Fitzpatrick) skin type V and VI
were excluded from the study.
The study adhered to the Declaration of Helsinki Principles and
the local medical ethical committees of the hospitals in the ﬁve
countries had approved the study design. Participants gave their
written informed consent.HPV serology analysis
Serum samples were stored at 80 1C and shipped on dry ice
to the German Cancer Research Center (DFKZ), Heidelberg,
Germany for serology analysis.
The samples were analysed for antibodies to the capsid protein
(L1) of the following 34 HPV types: beta types HPV-5, -8, -9, -15, -
17, -20, -23, -24, -36, -38, -49, -75, -76, -92, -93 and -96; gamma
types HPV-4, -48, -50, -60, -65, -95, -101 and -103; mu types
HPV-1 and -63, the nu type HPV-41, the cutaneous alpha types
HPV-2, -3, -7, and -27, and the mucosal alpha types HPV-6, -13
and -16 (Bernard et al., 2010). The antibody detection method
was based on glutathione S-transferase (GST) capture ELISA in
combination with ﬂuorescent bead technology (Sehr et al., 2001;
Waterboer et al., 2005). Brieﬂy, full-length viral proteins were
expressed in bacteria in fusion with an N-terminal GST-domain.
Glutathione cross-linked to casein was coupled to ﬂuorescence-
labeled polystyrene beads (SeroMap, Luminex, Austin, TX) and
GST-fusion proteins were afﬁnity-puriﬁed on the beads. Each
fusion protein was bound to a spectrally distinct bead set, and
fusion protein-loaded bead sets were mixed. Sera were incubated
with the mixed bead sets at a ﬁnal dilution of 1:100, and bound
antibodies were detected with biotinylated goat anti-human IgG
(HþL) secondary antibody and streptavidin–R-phycoerythrin.
A Luminex analyser (xMAP, Luminex) was used to identify the
internal colour of the individual beads and to quantify their
reporter ﬂuorescence (expressed as median ﬂuorescence intensity
(MFI) of at least 100 beads per set per serum).
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We performed two different types of analyses of our HPV
serology data; one where we analysed the MFI as a continuous
variable and one where we dichotomised the MFI to classify people
as either seropositive or seronegative to each HPV type. For this
latter analysis, we also classiﬁed people according to genus sero-
positivity. That is, whether they were seropositive to any of the
types within a particular genus. All statistical analyses were carried
out using SAS (version 9.1).
A standardised cut-off was used to determine seropositivity
(Michael et al., 2008).
We used linear regression to analyse associations between
factors such as age, sex and smoking and MFI for each individual
virus type, and logistic regression to analyse associations with
seropositivity for individual virus types and for overall genera. In
each case we included the MFI or serostatus at all time points in
the analysis, incorporating generalised estimating equations
(GEE) to take account of the intraperson correlation. Because
MFI was not normally distributed, we used the log of the MFI
value as the outcome variable in the linear regression analyses,
and expressed the results as the ratio of the geometric means.
We conducted several analyses to examine changes in HPV
serology over the 18 months following transplantation. Firstly, for
each virus we classiﬁed participants as being seropositive at all
time points (stably seropositive), seronegative at all time points
(stably seronegative), seroconverting (changing from seronegative
to seropositive over time), seroreverting (changing from seroposi-
tive to seronegative) and ﬂuctuating between seropositive and
seronegative over the available time points (ﬂuctuating). We used
simple descriptive statistics to describe the proportion of partici-
pants in each category for different viruses. Secondly, we used the
logistic and linear regression models described above to analyse
change in seropositivity or MFI over time, by using time point as the
dependent variable in each case. These analyses were adjusted for
age, sex and country of recruitment.Acknowledgments
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